{"name":"Zhuhai Trinomab Pharmaceutical Co., Ltd.","slug":"zhuhai-trinomab-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"zhuhaitrinomab.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"HTIG","genericName":"HTIG","slug":"htig","indication":"Advanced or metastatic solid tumors (in clinical development)","status":"phase_3"},{"name":"TNM001","genericName":"TNM001","slug":"tnm001","indication":"Advanced solid tumors (Phase 3 development)","status":"phase_3"},{"name":"TNM002","genericName":"TNM002","slug":"tnm002","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Adsorbed tetanus vaccine","genericName":"Adsorbed tetanus vaccine","slug":"adsorbed-tetanus-vaccine","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"HTIG","genericName":"HTIG","slug":"htig","phase":"phase_3","mechanism":"HTIG is a humanized anti-TIGIT monoclonal antibody that blocks the TIGIT immune checkpoint to enhance T-cell mediated anti-tumor immunity.","indications":["Advanced or metastatic solid tumors (in clinical development)"],"catalyst":""},{"name":"Adsorbed tetanus vaccine","genericName":"Adsorbed tetanus vaccine","slug":"adsorbed-tetanus-vaccine","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"TNM001","genericName":"TNM001","slug":"tnm001","phase":"phase_3","mechanism":"TNM001 is a trispecific antibody that simultaneously engages multiple immune checkpoints to enhance anti-tumor T-cell responses.","indications":["Advanced solid tumors (Phase 3 development)"],"catalyst":""},{"name":"TNM002","genericName":"TNM002","slug":"tnm002","phase":"phase_3","mechanism":"TNM002 is a monoclonal antibody targeting PD-1.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxQcWJPM1VBVUtZMklibGJ0UXMxZmJUU2EtTXF5c3BqV2NNTlF2VTY3aEcwTG9INi00QUJHaTlTbUNZTU1Fd0FubjFzTXk5VnpFYjF3QXZkZWw5a0xGdUZUNXZnYjdDb0hRZlphbE1sbXBENTF5S2tkQVBLUFc2M3c3R3FUY1BQWnlSUi03N1R5cmtaOEpMd0hFRUo3UmhCeG56YVdWZDR2VXdEN29ZeWw1SERRMjYtZV8xM3hvUjBCTzZCbkZ3UkJhUVp5ZDVmYnlWbnVzTUlkLWh0cmtGVHU1VlJLY1h0WWVXcUpTc0RpcDR3OTZNbm53blpfQm9Nems?oc=5","date":"2026-04-07","type":"pipeline","source":"Barchart.com","summary":"Herpes Zoster Treatment Market Size in the 7MM is projected to increase at a significantly CAGR by 2036, estimates DelveInsight - Barchart.com","headline":"Herpes Zoster Treatment Market Size in the 7MM is projected to increase at a significantly CAGR by 2036, estimates Delve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNc3JxT1NBS1hhdVAwUC1Na0Jma1hRcUk1Skw0TVp6Y2lPTE1ZRm5kLWJXRjVYY0xkTnNJQ0kxMklDemNFTllJMmQ4cGV0SzlxX0dGQl9rWjRYa2tlYldhWkNVTGxjTmVFUmN0NlRucGZ2STNRVG5sSlFiWm4xMDlFcmRHV2xPNjNwLUlvRUVUR2lhajNsXzVXcmhOaw?oc=5","date":"2026-03-25","type":"trial","source":"openPR.com","summary":"Respiratory Syncytial Virus Clinical Trial Pipeline Appears - openPR.com","headline":"Respiratory Syncytial Virus Clinical Trial Pipeline Appears","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxNc2c4SkNxa2x4OXNZbjktM1VjQWlJRnZUcWp3UC03MGRoMnlvU3FlbEdyM3hxaFU0MU1OQkhXbUpQNUI3QlB2dGYwRnpCcmRXN2ZiQzZsRlVyY0ZxaFNiM2RhN08xREotbURZTU1KcjRmWDlYMnlaRV9kVE1WTWdPcEJVUy1XV01CZDYxVGJWQjJSVE1DOVZHX2hNYjNsWElZd05CcWw0bjJ1QkxNd3VNVFgzVWtwTnlwbXFBUlBLbFg1TEtlQXptRzRoaDRUeVk2Z3RTbHo1TE5YSGxYcXFPaVVGQUprU284M0JIdHpsdw?oc=5","date":"2026-01-21","type":"regulatory","source":"Citeline News & Insights","summary":"Will Chinese Firms Take More Domestically Approved FIC Drugs To The World In 2026? - Citeline News & Insights","headline":"Will Chinese Firms Take More Domestically Approved FIC Drugs To The World In 2026? - Citeline News & Insights","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE1rQnJGN2RFYXZKcGVPeWlMSUtGRVJnRHdxOGlGc1RMOGt3N01Za2N0LUtoLUg2LU9FNng3WFhXdlRPYXFTTkNVMW14QmpPZWcxM0VnZ180QXV2NkplNFFTZ0t3?oc=5","date":"2025-10-24","type":"pipeline","source":"HKTDC Research","summary":"Biomedicine Boost As Zhuhai Links Up With Hong Kong and Macao - HKTDC Research","headline":"Biomedicine Boost As Zhuhai Links Up With Hong Kong and Macao","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":3,"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}